Getting on Board with Real-World Evidence About CDK 4/6 Inhibitors for HR+/HER2- mBC: Stay on Track with Shared Decision-Making
Host: Richard S. Finn, MD
\n\n\n \n
Evidence supports the notion that adding targeted agents that have a different mechanism of action than those that cause estrogen receptor interference can improve the benefits and outcomes seen with endocrine therapies alone in HR+/HER2- metastatic breast cancer (mBC). Clinical trial and real-world evidence show that CDK 4/6 inhibitors are safe and effective treatments for HR+/HER2- mBC. Real-world evidence can supplement clinical trial evidence and be more applicable to relevant community-based populations and clinical practice settings.
Optimal care of mBC involves the use of effective therapies that are supported by the latest evidence and guidelines, selected through a shared decision-making process, and individualized to each patient\u2019s needs. The educational Oncology Clinic features an up-to-date review of real-world evidence surrounding CDK 4/6 inhibitors in mBC that expands on available clinical trial evidence. Through case vignettes that model best practices in shared decision-making, expert faculty will demonstrate how to translate clinical trial and real-world evidence into discussions with patients.